检索结果-南通市图书馆

Chinese Medical Journal 2022年第24期135卷 3004-3006页

作者： Xinke Du Li Liu Lina Yang Lidong Sun Qingsen Ran Ying Chen Yujie Li Qing Yang Yajie Wang Xiaogang Weng Weiyan Cai Xiaoxin Zhu Qi Li Institute of Chinese Materia Medica China Academy of Chinese Medical SciencesBeijing 100700China

To the Editor:In breast cancer,it is the metastasis that makes a clear distinction between life and death.^([1,2])However,effective treatment targeted against metastasis remains an unmet clinical need.^([2,3])Accumulating evidence suggests that an essential step in metastasis is tumor cell acquisition of motility.^([2])Furthermore,epithelial-mesenchymal transition(EMT)initiates the early steps of tumor cell spread by endowing them with greater motility and invasiveness.

关键词： motility metastasis breast

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第4期8卷 1378-1380页

作者： Xiuwen Guan Fei Ma Qiao Li Shanshan Chen Ying Fan Jiayu Wang Yang Luo Pin Zhang Qing Liand Binghe Xu Department of Medical Oncology and State Key Laboratory of Molecular Oncology National Cancer Center/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Dear Editor,The irreversible pan-ErbB tyrosine kinase inhibitors(TKIs),including neratinib and pyrotinib,demonstrated more complete inhibition towards ErbB-family and promising antitumor activity compared to lapatinib,a reversible TKI.1 In the phase III NALA study for HER2-positive metastatic breast cancer(MBC)who were progressed after two lines of HER2-targeted regimens,2 significant improvement was observed in progression-free survival(PFS)in patients receiving neratinib combined with capecitabine when compared to lapatinib plus capecitabine(L+C)group.However,the 2.2-month PFS improvement in neratinib plus capecitabine cohort failed to translate to a significant benefit in the overall survival(OS,24.0 vs 22.2 months,P=0.2086).2 While another irreversible TKI,pyrotinib combined with capecitabine(P+C)achieved clinically and statistically significant improvement in the PFS and a trend of benefits in the OS when compared to the L+C group,based on the interim analysis(with the cutoff of March 31,2019)of the phase III PHOEBE study.3 Generally speaking,current evidence was still limited regarding the survival data of irreversible TKIs.

关键词： capecitabine HER2 breast

Clinicopathological features and prognoses of very young patients (≤35 years) with breast cancer:a retrospective population-based study in China

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2023年第12期136卷 1488-1490页

作者： Xin Ye Xiaoyun Zhou Qi He Zhiwei Wang Jie Wang Min Ji Department of breast Surgery The International Peace Maternity and Child Health HospitalSchool of MedicineShanghai Jiao Tong UniversityShanghai 200030China Department of breast Surgery Shanghai Key Laboratory of Embryo Original DiseasesShanghai 200030China

To the Editor:In China,very young breast cancer patients(≤35-year-old)make up approximately 10%of all breast cancer cases,compared to 2%in Western countries.This suggests that different morbidity may be caused by different geographic regions and ethnicities,even leading to different clinicopathological characteristics and prognoses.Tang et al[1]reported that very young breast cancer patients had poor disease-free survival(DFS),and the risk of disease progression was 1.557-fold higher than that for the elderly patients,but no difference was observed in overall survival(OS).However,few studies have focused on very young patients with breast cancer in China.Therefore,we conducted a retrospective population-based study to investigate the oncological outcomes of very young breast cancer patients.The studies involving human participants were reviewed and approved by the Ethics Committee of the International Peace Maternity and Child Health Hospital([No.GKLW]2021-37).

关键词： patients breast cancer

Oncologic efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

世界临床病例杂志 2023年第27期11卷 6398-6406页

作者： Hee Jun Choi Jun Ho Lee Chang Shin Jung Jai Min Ryu Byung Joo Chae Se Kyung Lee Jong Han Yu Seok Won Kim Seok Jin Nam Jeong Eon Lee Youn Joo Jung Hyun Yul Kim Department of Surgery Samsung Changwon HospitalSungkyunkwan University School of MedicineChangwon 51353South Korea Division of breast Surgery Department of SurgerySamsung Medical CenterSungkyunkwan University School of MedicineSeoul 06351South Korea Department of Surgery Pusan National University Yangsan HospitalPusan National University School of MedicineGyeongnam 50612South Korea

BACKGROUND breast cancer in young women has been shown to have an aggressive behavior and poor prognosis.AIM To evaluate the outcomes of young hormone receptor(HR)-positive patients with breast cancer treated with neoadjuvant chemotherapy(NAC),and the oncologic efficacy of gonadotropin-releasing hormone(GnRH)agonists.METHODS This retrospective study involved a prospectively enrolled cohort.We included patients diagnosed with invasive breast cancer who were treated with NAC followed by curative surgery at the Samsung Medical Center and Samsung Changwon Hospital between January 2006 and December 2017.Among patients with HR-positive and human epidermal grow factor 2(HER2)-negative breast cancer,we analyzed the characteristics and oncology outcomes between the patients equal to or younger than 35 years and the patients older than 35 years.RESULTS Among 431 patients with NAC and HR-positive/HER2-negative breast cancer,78 were 35 years old or younger,and 353 patients were older than 35 years.The median follow-up was 71.0 months.There was no statistically significant difference in disease free survival(DFS,P=0.565)and overall survival(P=0.820)between the patients equal to or younger than 35 years and the patients older than 35 years.The two groups differed in that the GnRH agonist was used more frequently in the group of patients equal to or younger than 35 years than in the other group(52.4%vs 11.2%,Pbreast cancer in the equal to or younger than 35 years group of patients with NAC.

关键词： Gonadotropin-releasing hormone Agonist Young breast Cancer

Granular cell tumor of the breast:A case report and review of literature

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2023年第33期11卷 8044-8049页

作者： Jun Yan Department of breast Surgery The University of Hong Kong-Shenzhen HospitalShenzhen 518000Guangdong ProvinceChina

BACKGROUND Granular cell tumor(GCT)of the breast(GCTB)is a rare neoplasm that can exhibit malignant characteristics both clinically and radiologically.This tumor can also coexist and colocalize with breast carcinoma.CASE SUMMARY We present a patient with this uncommon tumor and discuss the diagnostic and therapeutic approaches in order to further the knowledge of GCTB and prevent misdiagnosis and overtreatment.The characteristics of the tumor,methods of diagnosis,therapy and postoperative pathological outcomes were analyzed,and relevant literatures of GCTs were reviewed.The patient underwent surgery after core needle biopsy,and the excised neoplasm was sent for pathological examination.Histological analysis revealed nests of cells with abundant pink granular cytoplasm,confirming the diagnosis of GCTB.CONCLUSION As manifestations of GCT and malignancy can mimic each other,a careful histological examination is essential before major surgery.Treatment consisting of complete excision with close clinical follow-up is recommended.

关键词： Granular cell tumor breast Neoplasm Tumor Literature review Case report

Chronic pulmonary bacterial infection facilitates breast cancer lung metastasis by recruiting tumor-promoting MHCII^(hi) neutrophils

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第9期8卷 4305-4319页

作者： Teng Ma Yu Tang Taolin Wang Yang Yang Yige Zhang Ruihuan Wang Yongxin Zhang Yi Li Mingbo Wu Miao Tang Xueli Hu Chaoyu Zou Yuan Ren Huan Liu Qianhua Zhang Heyue Li Min Wu Jing Li Xikun Zhou Department of Biotherapy Cancer Center and State Key Laboratory of BiotherapyWest China HospitalSichuan University610041 ChengduChina Department of breast Surgery Sichuan Provincial People’s HospitalUniversity of Electronic Science and Technology of China610072 ChengduChina State Key Laboratory of Oral Diseases National Clinical Research Center for Oral DiseasesResearch Unit of Oral Carcinogenesis and ManagementChinese Academy of Medical SciencesWest China Hospital of StomatologySichuan UniversityChengduChina Drug Discovery Center Wenzhou InstituteUniversity of Chinese Academy of Sciences325001 WenzhouChina

breast cancer can metastasize to various organs,including the lungs.The immune microenvironment of the organs to be metastasized plays a crucial role in the metastasis of breast cancer.Infection with pathogens such as viruses and bacteria can alter the immune status of the lung.However,the effect of chronic inflammation caused by bacteria on the formation of a premetastatic niche within the lung is unclear,and the contribution of specific immune mediators to tumor metastasis also remains largely undetermined.Here,we used a mouse model revealing that chronic pulmonary bacterial infection augmented breast cancer lung metastasis by recruiting a distinct subtype of tumor-infiltrating MHCII^(hi) neutrophils into the lung,which exhibit cancer-promoting properties.Functionally,MHCII^(hi) neutrophils enhanced the lung metastasis of breast cancer in a cell-intrinsic manner.Furthermore,we identified CCL2 from lung tissues as an important environmental signal to recruit and maintain MHCII^(hi) neutrophils.Our findings clearly link bacterial-immune crosstalk to breast cancer lung metastasis and define MHCII^(hi) neutrophils as the principal mediator between chronic infection and tumor metastasis.

关键词： metastasis lung breast

Triple combination targeting PI3K,ER,and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2023年第6期43卷 720-725页

作者： Mikkel G.Terp Martina Tuttolomondo Neil Portman Sidse Ehmsen Lene E.Johansen Martin Bak Elgene Lim Henrik J.Ditzel Department of Cancer and Inflammation Research Institute of Molecular MedicineUniversity of Southern DenmarkOdenseDenmark Garvan Institute of Medical Research DarlinghurstSydneyNew SouthWalesAustralia St.Vincent’s Clinical School Faculty of MedicineUniversity of New SouthWales SydneySydneyNew South WalesAustralia Department of Oncology Institute of Clinical ResearchOdense University HospitalOdenseDenmark Department of Pathology Sydvestjysk SygehusEsbjergDenmark Academy of Geriatric Cancer Research(AgeCare) Odense University HospitalOdenseDenmark

Dear Editor,Despite the improved outcome of advanced estrogen receptor-positive(ER+)breast cancer patients treated with endocrine therapy in combination with either a cyclindependent kinase 4/6 inhibitor(CDK4/6i)or a phosphoinositide 3-kinase inhibitor(PI3Ki),the disease will eventually progress,and the optimal treatment strategy upon progression remains undefined[1-4].To address this,we developed MCF-7-and T47D-derived PIK3CAmutated breast cancer cell lines[5]resistant to combined CDK4/6i palbociclib and fulvestrant(MPF-R and TPFR)or combined PI3Ki alpelisib and fulvestrant(MAF-R and TAF-R),respectively(Supplementary Materials and Methods).Drug-sensitive isogenic cells(M-S and T-S)grown in parallel with MPF-R and TPF-R cells and the original MCF-7/S0.5 and T47D cells were analyzed for comparison.

关键词： PIK3CA breast cancer

A novel histone deacetylase inhibitor exerts promising anti-breast cancer activity via triggering AIFM1-dependent programmed necrosis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2022年第11期42卷 1207-1211页

作者： Peipei Shan Feifei Yang Jie Yu Lirong Wang Yuhua Qu Huiran Qiu Hua Zhang Sujie Zhu Institute of Translational Medicine The Affiliated Hospital of Qingdao UniversityCollege of MedicineQingdao UniversityQingdaoShandong 266021P.R.China School of Biological Science and Technology University of JinanJinanShandong 250022P.R.China Qingdao Center Hospital:Qingdao Center Medical Group QingdaoShandong 266042P.R.China

Dear Editor,breast cancer is one of the most lethal cancers in women,with many patients still succumbing to this dis-ease[1].Accumulating evidence demonstrates that histone deacetylase inhibitors(HDACIs)are a promising therapeu-tic intervention for breast cancer[2],and many of them have shown favorable anti-cancer activities in both pre-clinical and clinical settings[3].However,most current HDACIs only exhibit limited efficacy against solid tumors with toxic side effects and readily produce drug resistance[4].Therefore,it is necessary to develop new HDACIs with improved anti-tumor activities and decreased toxic-ities for breast cancer therapeutics and investigate their mechanism of action.

关键词： breast cancer clinical

Combination of anti-PD-L1 antibody with peptide MEL-dKLA targeting M2 tumor-associated macrophages suppresses breast cancer metastasis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2022年第4期42卷 345-349页

作者： Chanju Lee Hyunji Lee Hayoon Cho Soyoung Kim Ilseob Choi Young-Sik Hwang Hyunju Jeong Hogi Jang Sehyun Pak Deok-Sang Hwang Ik-Hwan Han Hyunsu Bae Department of Physiology College of Korean MedicineKyung Hee University26 Kyungheedae-roDongdaemoon-guSeoul 02447Republic of Korea Department of Science in Korean Medicine College of Korean MedicineKyung Hee University26 Kyungheedae-roDongdaemoon-guSeoul 02447Republic of Korea Cancer Immunology Branch National Cancer Center323 Ilsan-roIlsandong-guGoyang 10408Republic of Korea Department of Clinical Korean Medicine Graduate SchoolKyung Hee University26 Kyungheedae-roDongdaemoon-guSeoul 02447Republic of Korea

Dear editors,breast cancer is a leading cause of cancer-related deaths worldwide and is the most common cancer among women[1].The cause of death in patients with breast cancer is not the primary tumor itself but mainly metastasis.The most common sites of breast cancer metastasis include the bones,lungs,brain,lymph nodes,and liver.Importantly,lung metastasis has been a particular concern as it results in high patient morbidity and mortality rates[2].

关键词： metastasis breast mortality

Dynamic epi-transcriptomic landscape mapping with disease progression in estrogen receptor-positive breast cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2023年第5期43卷 615-619页

作者： Stephen Keelan Mihaela Ola Sara Charmsaz Sinéad Cocchiglia Daniela Ottaviani Seán Hickey Siobhan Purcell Fiona Bane Aisling Hegarty Ben Doherty Katherine Sheehan Lance Hudson Nicola Cosgrove Benjamin Roux Muriel Laine Geoffrey Greene Damir Varešlija Arnold Konrad Hill Leonie Young Endocrine Oncology Research Group Department of SurgeryRoyal College of Surgeons in IrelandUniversity of Medicine and Health SciencesDublinIreland Department of Surgery Beaumont HospitalDublinIreland Department of Pathology Beaumont HospitalDublinIreland Ben May Department for Cancer Research Department of Biochemistry and Molecular BiologyThe University of ChicagoChicagoILUSA The School of Pharmacy and Biomolecular Sciences The Royal College of Surgeons University of Medicine and Health SciencesDublinIreland Beaumont Royal College of Surgeons in Ireland Cancer Centre Beaumont HospitalDublinIreland

Dear Editor,The molecular determinants that drive breast cancer progression to metastasis are complex and partly controlled by nucleic acid epi-modifications[1].Although DNA-methyl modifications in breast cancer metastasis have been well described,there is limited understanding of the role of RNA methylation in advanced disease[2].This study aimed to provide an understanding on the role of the epitranscriptome in estrogen receptor-positive(ER+)breast cancer progression to metastasis.

关键词： breast metastasis cancer